Concentrix commissions Everest Group to study driving AI value from transforming operating models, not simply automating work

NEWARK, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced findings of an independent market study, conducted by industry analyst firm, Everest Group. The report explores the operating models that successful businesses will use to orchestrate people, AI, data, and technology to deliver better business and customer outcomes.

Reinvent or Evolve: Intelligent Operating Models Shaping AI-Enabled Customer Journeys, discusses that while many enterprises have adopted AI, most could achieve better outcomes by maximizing AI as a key enabler of a broader operating strategy.

This report demonstrates that organizations need to redesign their operating model purposely for AI, with two core paths to maximize competitive advantage: Evolution, where AI makes human-led operations smarter and more efficient through human & AI collaboration, and Reinvention, which sees a wholesale redesign around a native AI and agentic operating environment. Currently, only about 16% of enterprises expect AI to autonomously lead most customer interactions next year.

Based on research independently conducted across enterprise decision-makers, the report finds the biggest barrier to AI success isn’t the AI itself, it’s the ability to establish governance, and orchestrate execution across functions, technologies, and teams at scale.

“The conversation around AI often focuses on technology adoption, but the bigger challenge is operating model transformation,” said Sharang Sharma, Vice President, Everest Group. “As enterprises move toward AI-enabled customer journeys, they need partners that can create a clear framework for governance, accountability and execution. Success will depend less on deploying AI tools and more on creating the organizational readiness to scale them effectively across the business.”

“The biggest opportunity organizations have with AI isn’t to automate what’s already there. It’s to create entirely new ways of delivering value,” said Chris Caldwell, President & CEO of Concentrix. “The organizations seeing the strongest results are redesigning customer experiences, embedding AI into the flow of work, and combining human expertise with intelligent technology to achieve better business outcomes. That’s where the next generation of competitive advantage will emerge.”

The report found that organizations are moving beyond AI as a standalone tool, to reshaping customer experiences through operating model redesign. For example, a leading retailer was able to deliver responses 31% faster with Agentic AI, creating a scalable path to lower cost-to-serve.

As AI moves from experimentation to enterprise scale, businesses need partners that can orchestrate strategy, consulting, technology, and operations into a united ecosystem. Through its proprietary iX Suite, Concentrix helps clients unite people, technology, data, and operations to evolve existing journeys and enable AI-native experiences.

To learn more about the study and its findings, visit Reinvent or Evolve: Intelligent Operating Models Shaping AI-Enabled Customer Journeys.

About Everest Group
Everest Group is a leading research firm helping business leaders make confident decisions. The firm’s research and advisory services help organizations navigate market challenges, strengthen business performance, and drive transformative outcomes across technology, business processes, engineering, talent, sustainability, and sourcing.

About us: Powering a World That Works  
Concentrix (NASDAQ: CNXC), is the Fortune 500® technology and services company, helping the world’s best brands create intelligent operations that perform in the real world. We design, build, and run integrated human and AI solutions, harnessing the insight from billions of real-world interactions to help 2000+ of the world’s most complex organizations solve their toughest business challenges. Backed by 20+ years of operational experience and battle tested AI, we’re the intelligent transformation partner that helps clients across every major industry move from ambition to measurable, scalable performance. Virtually everywhere. Visit concentrix.com to learn more. 

Media Contact:
Marketing & Communications
Concentrix Corporation
media@concentrix.com

From Fortune. ©2026 Fortune Media (USA) Corporation. All rights reserved. Used under license.  Fortune and Fortune 500 are registered trademarks of Fortune Media (USA) Corporation and are used under license.  Fortune and Fortune Media (USA) Corporation are not affiliated with, and do not endorse products or services of, Concentrix.

Safe Harbor Statement
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the company’s capabilities and positioning to deliver business outcomes and solve challenges for its clients, and statements that include words such as believe, expect, may, will, provide, could and should and other similar expressions. These forward-looking statements are inherently uncertain and involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the company’s ability to successfully execute its strategy, competitive conditions in the company’s industry, and other factors contained in the Company’s Annual Report on Form 10-K for the fiscal year ended November 30, 2025 filed with the Securities and Exchange Commission and subsequent SEC filings. We do not undertake a duty to update forward-looking statements, which speak only as of the date on which they are made.

Copyright 2026 Concentrix Corporation and its subsidiaries. All rights reserved. Concentrix, the Concentrix logo, and all other Concentrix company, product and services names and slogans are trademarks or registered trademarks of Concentrix Corporation and its subsidiaries.

FALLS CHURCH, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) announced today that its third quarter 2026 financial results will be released on Tuesday, October 20, 2026, prior to the market opening. The earnings announcement, and accompanying earnings presentation, will be available on the company’s website at http://investor.northropgrumman.com.

Earnings Call Webcast

The company will host a live, audio only, earnings call webcast at 9:30 a.m. ET the same day. This webcast can be accessed on the company’s website at http://investor.northropgrumman.com. A replay of the webcast will be available shortly after the call and will remain available for a limited time.

About Northrop Grumman
Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared purpose to solve our customers’ toughest problems, our employees define possible every day.

Contact: newsbureau@ngc.com

Randy Sinclair (Investors) 
randy.sinclair@ngc.com

Appointment strengthens GYG’s leadership as the Company expands GameGolf and Altus Sports Group, building a broader sports technology ecosystem

PALO ALTO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Game Your Game, Inc. (Nasdaq: GYGY) (“GYG” or the “Company”), an AI-powered sports performance technology company, today announced the appointment of Mujtaba Elgoodah as a Strategic Advisor.

The appointment comes as the Company accelerates its growth strategy across two complementary businesses: GameGolf, its AI-powered golf technology platform, and Altus Sports Group (“ASG”), its majority-owned subsidiary focused on talent representation, athlete branding and sports marketing. Elgoodah will serve the Company and ASG in a non-executive, advisory capacity.

Elgoodah brings nearly a decade of experience at the intersection of sports, technology, media and investment. He has worked with leading sports organizations and executives, including the National Basketball Players Association, where he serves as an advisor to the Executive Director. He previously spent five years with the Golden State Warriors, including the team’s 2022 NBA championship season.

Elgoodah is also an investor and advisor across a range of sports and technology ventures, including investments and strategic roles with The Bay Golf Club, Oakland Roots Sports Club and Caledonian Braves Football Club.

“Mujtaba brings a perspective that is particularly valuable to us as we expand ASG,” said Soumya Das, Chairman and CEO of GYG. “He understands the sports business from the athlete, team, league, media and investment perspectives. That combination can help us identify partnerships and opportunities that extend well beyond golf.”

Mujtaba Elgoodah said, “Sports is undergoing a fundamental transformation as technology changes how athletes perform, fans engage and businesses create value. Game Your Game is building a compelling platform across both golf and the broader sports ecosystem, and I am excited to help the team pursue those opportunities.”

About Game Your Game, Inc.

Game Your Game, Inc. (Nasdaq: GYGY) is an AI-powered sports performance technology company. The Company develops and markets the GameGolf KZN AI™ platform — an integrated golf performance ecosystem of proprietary shot-tracking hardware and subscription-based software solutions. The platform leverages advanced GPS tracking, embedded neural network technology, and AI-powered analytics to provide golfers of all skill levels with real-time insights, on-course strategy recommendations, and personalized performance data. Game Your Game’s technology has been adopted by golfers in more than 140 countries, with over 36,000 golf courses mapped and an estimated number of more than 300 million shots tracked across the lifetime of its platforms. The Company is headquartered in Palo Alto, California. For more information, visit www.gameyourgame.com.

About Altus Sports Group, Inc.

Altus Sports Group, Inc., a majority-owned subsidiary of Game Your Game, Inc., was formed in August 2026 to build a connected platform for the sports business across talent representation, athlete branding and sports marketing. For more information, visit www.altus-sports.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause the Company’s or ASG’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s growth strategy, the expansion of GameGolf and ASG, the development of a broader sports technology ecosystem, and the anticipated contributions of Mujtaba Elgoodah to the Company and ASG. These statements are only predictions and involve known and unknown risks and uncertainties, including, but not limited to, the Company’s ability to expand beyond performance tracking products and offerings; the Company’s ability to retain the services of, and realize the anticipated benefits from, its strategic advisors; the Company’s ability to develop ASG’s business and realize the anticipated benefits therefrom; the ability of ASG to attract and retain talent agents, clients and key personnel, including ASG’s founding team; the ability of ASG to identify, negotiate, finance and complete any acquisitions, investments or partnerships on acceptable terms or at all; ASG’s ability to effectively compete in the sports representation and marketing industries; ASG’s ability to comply with regulatory and league rules applicable to talent representation; ASG’s ability to attract athletes to participate in its platform through the engagement of talent agents and sports marketers; and other factors identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s Registration Statement on Form S-1 (File No. 333-296763), as amended, which was declared effective by the SEC on July 28, 2026, and the prospectus forming a part thereof, [the Company’s Registration Statement on Form S-1 filed with the SEC on August 21, 2026, as amended,] and other periodic and current reports filed with the SEC from time to time, which are available at www.sec.gov. Furthermore, the Company operates in a competitive environment where new and unanticipated risks may arise. Accordingly, you should not place undue reliance on forward-looking statements as a prediction of actual results. The Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press release, except as required by law.

Investor and Media Contact
KCSA Strategic Communications
Phil Carlson, Managing Director
GYGY@KCSA.com

New Filing Seeks Broad Protection Around Creative Medical’s Cell-Free Regenerative Platform, Including Product Composition, Functional Potency, Manufacturing Controls and Additional Therapeutic Applications

PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome™, the Company’s proprietary cell-free regenerative medicine platform.

The newly filed application builds upon Creative Medical’s existing regenerative medicine intellectual property and seeks protection across multiple aspects of the Ultrasome platform, including proprietary product composition, biological potency, manufacturing and quality-control methodologies, stability characteristics, delivery approaches and therapeutic applications.

The filing is intended to strengthen the Company’s long-term intellectual property position as Creative Medical advances Ultrasome beyond its initial osteoarthritis program and evaluates the platform’s potential across additional areas of regenerative medicine.

“As our understanding of the Ultrasome platform continues to advance, we believe it is important to protect not only its therapeutic applications, but also the underlying product characteristics, biological activity and manufacturing framework that distinguish the platform,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “This filing represents another step in building a broad intellectual property estate around what we believe can become a highly scalable cell-free regenerative medicine platform.”

Building Intellectual Property Around Product Function, Not Simply Particle Identity

Creative Medical’s development strategy for Ultrasome incorporates both physical product characterization and biologically relevant functional testing designed to evaluate activity associated with tissue protection and regenerative signaling.

The newly filed provisional patent application seeks intellectual property protection around multiple aspects of this approach, including methods intended to characterize the biological activity and consistency of manufactured product.

Management believes that integrating product composition, functional potency and manufacturing control may provide important differentiation as the field of extracellular-vesicle and secretome-based therapeutics continues to evolve.

The patent application also includes intellectual property directed toward methods for evaluating changes in product biological activity that may not be reflected by particle measurements alone.

“A central component of our development strategy is establishing reproducible biological activity across manufactured product,” Warbington added. “We believe that connecting manufacturing, product characterization and functional performance is important both scientifically and strategically as we advance this platform.”

Builds on Previously Announced Ultrasome™ Knee Osteoarthritis Program

The new patent filing follows Creative Medical’s previously announced pilot study evaluating Ultrasome in patients with knee osteoarthritis.

As announced in April 2026, the study reported that approximately 93% of participants demonstrated clinically meaningful improvements in mobility and pain, and no serious adverse events were reported.

The Company continues to view osteoarthritis as an important initial application for Ultrasome while exploring the broader potential of the platform across regenerative medicine.

The new provisional filing includes intellectual property intended to preserve development flexibility for musculoskeletal and cartilage disorders as well as selected clinical applications. These additional applications remain in various stages of research and development and should not be interpreted as evidence of clinical efficacy or regulatory approval in those indications.

Extending a GMP-Based Regenerative Medicine Platform

Ultrasome is being developed from Creative Medical’s proprietary Olastrocel™ regenerative medicine platform.

The underlying cellular source is derived from an independently validated Good Manufacturing Practice master cell bank, with manufacturing and quality information maintained within a U.S. Food and Drug Administration Drug Master File.

A Drug Master File is a confidential regulatory submission containing manufacturing and quality information and does not itself constitute FDA approval, clearance or authorization of a therapeutic product.

Creative Medical believes the ability to leverage a controlled cellular starting material across both cell-based and cell-free programs may support future manufacturing scalability, product consistency and expansion of its regenerative medicine pipeline.

Expanding Creative Medical’s Intellectual Property Portfolio

The new application is part of Creative Medical’s strategy of building intellectual property protection around multiple layers of its regenerative medicine technologies, including:

  • proprietary cell-free compositions;
  • functional biological characteristics;
  • manufacturing and quality-control methodologies;
  • stability and product-release approaches;
  • targeted delivery methods; and
  • therapeutic applications across selected regenerative medicine indications.

As a provisional patent application, the filing establishes an initial U.S. priority date for the disclosed subject matter and provides the Company with the opportunity to pursue U.S. and international patent protection through subsequent filings.

The provisional application has not been examined by the U.S. Patent and Trademark Office, and there can be no assurance regarding the scope or issuance of any future patent claims.

Strategic Focus

Creative Medical intends to continue advancing its intellectual property portfolio in parallel with its clinical and translational development programs.

Management believes a combination of clinical development, proprietary manufacturing, functional product characterization and intellectual property protection may create multiple opportunities for future platform development, strategic collaboration and value creation.

“Our goal is to build durable value around the science,” Warbington concluded. “We believe the combination of our clinical-stage regenerative platform, expanding cell-free programs and growing intellectual property portfolio positions Creative Medical to pursue multiple high-value opportunities while maintaining disciplined development of our core programs.”

About Ultrasome™

Ultrasome™ is Creative Medical Technology Holdings’ proprietary cell-free regenerative medicine platform derived from the Company’s umbilical cord tissue technology. The platform is being developed to deliver biologically active regenerative signals through scalable, off-the-shelf formulations for potential use across selected degenerative and regenerative medicine applications.

Ultrasome’s initial clinical development has focused on osteoarthritis of the knee.

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a biotechnology company advancing regenerative medicine therapies derived from adult and perinatal cell technologies. The Company’s programs span multiple areas of regenerative medicine and are designed to translate proprietary cellular and cell-free technologies into therapeutic opportunities for patients with significant unmet medical needs.

For more information, please visit www.creativemedicaltechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the potential scope and value of the Company’s intellectual property portfolio; the development, scalability, manufacturing, potential therapeutic applications and commercial potential of Ultrasome™; future patent prosecution and patent issuance; future clinical and translational development; potential strategic collaborations; and the Company’s plans to evaluate additional regenerative medicine indications. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, risks associated with patent prosecution and enforcement, clinical development, regulatory review, manufacturing, scientific validation, financing, market acceptance and other risks described in the Company’s filings with the Securities and Exchange Commission.

A provisional patent application is not examined by the USPTO and does not guarantee that a patent will issue or that any subsequently issued claims will provide commercially meaningful protection.

Creative Medical Technology Holdings, Inc. undertakes no obligation to update forward-looking statements except as required by applicable law.

Investor & Media Contacts

Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
www.creativemedicaltechnology.com

Investor Relations / The Equity Group Inc.
Devin Sullivan
devin.sullivan@theequitygroup.com Conor Rodriguez
conor.rodriguez@theequitygroup.com

DELTA, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF |FSE: ID4), a critical minerals refining and lithium-ion battery upcycling company, announces that it has invested USD 1,000,000 in convertible preferred stock of global fusion technology provider Type One Energy Group (“Type One Energy”). The transaction reflects RecycLiCo’s broad commitment to supporting technologies across the advanced energy and critical-materials ecosystem.

Type One Energy is mission-driven to provide sustainable, affordable fusion power to the world. Established in 2019 and venture-backed in 2023, the company is led by a team of globally recognized fusion scientists with a strong track record of building state-of-the-art stellarator fusion machines and veteran business leaders experienced in scaling companies and commercializing energy technologies. Type One Energy applies proven advanced manufacturing methods, modern computational physics, and high-field superconducting magnets to develop its optimized stellarator fusion energy system. Its FusionDirect™ development program pursues the lowest-risk, shortest-schedule path to a commercial fusion power plant over the coming decade, using a partner-intensive and capital-efficient strategy. Type One Energy is committed to community engagement in the development and deployment of its clean energy technology. 

“We are pleased to support Type One Energy and the advancement of its technology,” said Richard Sadowsky, Interim Chief Executive Officer, RecycLiCo. “RecycLiCo operates at the intersection of critical materials, advanced technology and the global transition to sustainable energy to which Type One’s next-generation fusion technology will be an important contributor.”

About RecycLiCo

RecycLiCo Battery Materials Inc. is a critical minerals refining company specializing in the use of advanced hydrometallurgical technologies for processing mined ore and the upcycling of lithium-ion battery materials. RecycLiCo’s processes efficiently recover battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, supporting energy storage as well as broader industrial applications. RecycLiCo’s business focus aligns with the global demand for future-ready, responsible supply chains and the growing movement to strengthen domestic sourcing of critical materials.

For more information, please contact:
Paola Ashton
PRA Communications
Telephone: 604-681-1407
Email: pashton@pracommunications.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward–looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Nasdaq announced today that it will delist the Class A Common Stock and Warrants of Abpro Holdings, Inc. Abpro Holdings, Inc’s Class A Common Stock and Warrants were suspended on February 23, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of CIMG Inc. CIMG Inc.’s common stock was suspended on March 6, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Ordinary Shares of MDJM LTD. MDJM LTD’s Class A Ordinary Shares were suspended on March 20, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Ordinary Shares of Davis Commodities Limited. Davis Commodities Limited’s Class A Ordinary Shares were suspended on March 25, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of Maxeon Solar Technologies, Ltd. Maxeon Solar Technologies, Ltd.’s ordinary shares were suspended on May 1, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Sangamo Therapeutics, Inc. Sangamo Therapeutics, Inc.’s common stock was suspended on May 5, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Aditxt, Inc. Aditxt, Inc.’s common stock was suspended on June 25, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of Semilux International Ltd. Semilux International Ltd.’s ordinary shares were suspended on June 8, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Ordinary Shares of Pitanium Limited. Pitanium Limited’s Class A Ordinary Shares were suspended on July 16, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Smart Powerr Corp. Smart Powerr Corp.’s common stock was suspended on July 21, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of SPAR Group, Inc. SPAR Group, Inc.’s common stock was suspended on July 23, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Nuvve Holding Corp. Nuvve Holding Corp.’s common stock was suspended on July 24, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A Common Stock of Vestand Inc. Vestand Inc.’s Class A Common Stock was suspended on July 27, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of Empro Group Inc. Empro Group Inc.’s ordinary shares was suspended on July 27, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares, units, and warrants of Keen Vision Acquisition Corporation. Keen Vision Acquisition Corporation’s securities were suspended on August 3, 2026 and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Nusatrip Incorporated. Nusatrip Incorporated’s common stock was suspended on August 12, 2026 and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares of FAST TRACK GROUP. FAST TRACK GROUP’s ordinary shares were suspended on August 18, 2026 and have not traded on Nasdaq since that time.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.

BRENTWOOD, Tenn., Sept. 17, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced it has completed the previously announced sale of its ownership interests in its Idaho Falls facilities to Intermountain Health.

Under the terms of the Securities Purchase Agreements, Surgery Partners received $797 million in gross proceeds and $587 million in net cash proceeds at closing, subject to customary post-closing adjustments. The transaction includes Mountain View Hospital and Idaho Falls Community Hospital (together, referred to as Idaho Falls Facilities). Under Intermountain Health leadership, physician ownership of Mountain View Hospital will remain unchanged.

“With the completion of this important transaction, Surgery Partners enters a new chapter better positioned for long-term growth as a pure-play short-stay surgical provider,” said Eric Evans, Chief Executive Officer of Surgery Partners. “As we recently disclosed in our second quarter earnings call, our core business is delivering strong results, with same facility revenue growth driven by our continued focus on higher-acuity procedures and a differentiated operating platform. Our updated full-year 2026 outlook underscores the benefit of our portfolio optimization actions, with this transaction expected to be accretive to adjusted earnings growth on an annual basis, in addition to reducing our balance sheet leverage and improving free cash flow conversion. We are encouraged by our recent momentum and remain confident in our long-term strategy and ability to deliver sustained value for stockholders.”

Financial Highlights

  • The transaction values the combined Idaho Falls Facilities at approximately $1.15 billion, with total consideration to Surgery Partners of approximately $797 million of gross proceeds and $587 million of net cash proceeds.
  • Transaction proceeds represent an approximately 7x multiple based on the Idaho Falls Facilities’ last 12 months adjusted EBITDA performance (through June 30, 2026), and an approximately 17x multiple based on average distributions received from Idaho Falls over the past three years.
  • Balance sheet leverage, as calculated under the Company’s credit agreement, is expected to improve by 30bps, from 4.4x at the end of Q2 2026.
  • Transaction proceeds will be used primarily to pay down debt.

Operational Highlights

This transaction significantly streamlines Surgery Partners’ business and portfolio. Excluding the Idaho Falls Facilities, the Company expects:

  • 50% reduction in Medicaid payor mix, with new annualized mix expected to be under 2% of revenue.
  • 100% elimination of neonatology and obstetrics service lines.
  • 50% reduction in intensive care beds and majority reduction in total emergency department visits.
  • 75% reduction in non-surgical admissions.
  • 100% elimination of inpatient pediatrics businesses.
  • 100% reduction in retail and compounding pharmacy service lines.

Updated 2026 Guidance

  • Full-year 2026 revenue guidance is in the range of $3.08 billion to $3.18 billion and Adjusted EBITDA guidance is at least $489 million, reflecting the removal of the Idaho Falls Facilities’ contribution for the remaining portion of the year.
  • On a pro forma basis, excluding the Idaho Falls Facilities for the full-year 2026, revenue guidance is in the range of $2.60 billion to $2.67 billion and Adjusted EBITDA guidance is at least $414 million.

Advisors

Barclays served as the lead financial advisor to Surgery Partners, and McDermott Will & Schulte LLP served as its legal counsel. RBC Capital Markets, LLC served as the lead financial advisor to Intermountain Health, and Hall, Render, Killian, Heath & Lyman, P.C. served as its legal counsel.

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

About Idaho Falls Facilities

The Idaho Falls Facilities have built a long-standing reputation as preferred providers and leaders in delivering high-quality, affordable care for the Idaho Falls region. Mountain View Hospital was founded in 2002 and has grown into a leading surgical hub and Level III NICU, with the opening of the Idaho Falls Community Hospital in 2019 adding scalable acute care capabilities. Combined, the locations employ over 150 physicians and include 126 beds with a breadth of services across nine surgical specialties and a diverse range of additional service lines, including oncology, emergency department and ICU services, and neonatology.

About Intermountain Health

Headquartered in Utah with locations in six states and additional operations across the western U.S., Intermountain Health is a nonprofit system of 34 hospitals, approximately 400 clinics, medical groups with some 4,600 employed physicians and advanced care providers, a nonprofit health plan called Select Health with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements, including those regarding growth, our anticipated operating results for future periods and other similar statements. These statements can be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “continues,” “estimates,” “predicts,” “projects,” “forecasts,” “may,” “could,” and similar expressions. All forward-looking statements are based on current expectations and beliefs as of the date of this release and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from the expectations discussed in, or implied by, the forward-looking statements. Many of these factors are beyond our ability to control or predict including, without limitation, the possibility that the anticipated benefits of the sale to the Company are not realized as expected, the potential adverse effect of the announcement on the market price of, or trading in, the Company’s securities and on the Company’s business relationships, operating results, and business generally, including the ability to retain key personnel; potential litigation relating to the transaction that could be instituted against the Company or its affiliates, officers, or directors, and the effects of any outcomes related thereto; reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired or developed businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring or operating surgical facilities; the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties identified and discussed from time to time in the Company’s reports filed with the Securities and Exchange Commission (the “SEC”), including in Item 1A under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other reports filed with the SEC. Except as required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures. A “non-GAAP financial measure” is defined as a numerical measure of a company’s financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles in the United States (“GAAP”). We present non-GAAP financial measures when we believe that the additional information is useful and meaningful to investors. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-GAAP financial measures is not intended to be a substitute for, and should not be considered in isolation from, financial measures reported in accordance with GAAP. We are not able to project components of the 2026 Adjusted EBITDA guidance and therefore cannot provide a reconciliation of the forward-looking non-GAAP financial measures.

Contact

Surgery Partners Investor Relations
(615) 234-8940
IR@surgerypartners.com

Company in Full Compliance with All Nasdaq Continued Listing Requirements

FREEHOLD, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) — Change Agents Corporation (Nasdaq: CHGA) (“Change Agents” or the “Company”), a developer of agentic artificial intelligence (“AI”) software solutions advancing into AI-enabled autonomous air surveillance and air defense counter-unmanned aerial systems (“C-UAS”) technologies, today announced that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on September 15, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.

As previously disclosed, the Company was notified by Nasdaq on April 15, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq has now determined that the closing bid price of the Company’s common stock was at or above $1.00 per share for 10 consecutive business days from August 31, 2026 to September 14, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq has advised the Company that the matter has been closed.

“We are pleased to have regained compliance with Nasdaq’s minimum bid price requirement, which represents an important step as we continue executing on the transformation of Change Agents,” said Michael Mathews, Director of Change Agents Corporation. “Over the past several months, we have taken meaningful steps to advance our strategy across both agentic AI software and AI-enabled autonomous defense technologies. With Phase 2 development of our Catch-Up platform now complete and beta testing ongoing, alongside the continued expansion of our autonomous air defense and counter-UAS initiatives, we believe we are building a stronger foundation to pursue multiple high-growth market opportunities and create long-term value for our shareholders.”

About Change Agents Corporation

Change Agents Corporation (Nasdaq: CHGA) is a developer of agentic artificial intelligence software solutions. The Company is expanding its strategy into AI-enabled autonomous air defense and counter-UAS technologies through its wholly owned subsidiary, Autonomous Air Defense LLC. Change Agents is evaluating technologies, strategic partnerships and acquisition opportunities intended to position the Company in markets where artificial intelligence, autonomous systems and advanced defense technologies converge. The Company’s current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, Change Agents is focused on delivering innovative AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns. The Company is seeking to expand into various high growth sectors that are expected to benefit from artificial intelligence.

Change Agents is also distributing the KetoAir™ breathalyzer device a non-invasive consumer breathalyzer that measures ketosis levels and is sold in North America, which is registered with the U.S. Food and Drug Administration as a Class I medical device.

For more information about Change Agents Corp, please visit www.changeagentscorp.com.

Forward-Looking Statements

Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements include, but are not limited to, statements regarding the Company’s strategy, the formation and anticipated activities of Autonomous Air Defense LLC, the evaluation of potential acquisitions, strategic investments and partnerships, the size and growth of the counter-UAS market, and future business plans. Market data cited herein is derived from third-party sources that the Company believes to be reliable but has not independently verified. The Company has no operating history in the defense sector, and there can be no assurance that it will complete any transaction, develop or acquire any counter-UAS technology, or generate any revenue from this initiative. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC’s website (http://www.sec.gov), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.

Contact Information:
Change Agents Corp.
ir@changeagentscorp.com 

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
CHGA@crescendo-ir.com 

Initial order establishes second satellite laser communication customer and supports development roadmap targeting production in approximately 6-12 months

LITTLETON, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (Nasdaq: POCI) (the “Company”), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of an initial $50,000 development order from a U.S. space technology company developing a new satellite constellation. The order supports early engineering work on laser communication subassemblies intended for use in Optical Communication Terminals (OCTs) on the customer’s satellite systems. This engagement represents the Company’s second satellite customer.

Work will begin promptly in support of the customer’s accelerated development schedule. This early phase is expected to be completed in approximately one month with the customer’s stated goal to begin production within six to twelve months.   Precision Optics expects to finalize a comprehensive engineering agreement to develop final designs followed by the transition to production.

“Adding another satellite customer is an important step in expanding an area that has quickly become a major growth driver for Precision Optics,” said Dr. Joe Forkey, CEO of Precision Optics. “We have an opportunity to apply our experience to a new satellite laser communications program and quickly build another long-term production relationship. This initial order allows us to move with urgency as we work toward a broader engineering scope and the customer’s production goal.”

The new program involves subassemblies analogous to those supplied for the Company’s existing satellite program but also represents an opportunity to move further up the value chain within OCT systems. Precision Optics’ vertically integrated, U.S.-based capabilities enable it to work with customers from early design and prototyping through production, helping translate complex optical requirements into assemblies designed for efficient high volume manufacturing.

About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division’s high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company’s products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company’s filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Company Contact:                                         
PRECISION OPTICS CORPORATION
550 King Street, Building A, Suite 100
Littleton, MA 01460
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com

MONTREAL, Sept. 17, 2026 (GLOBE NEWSWIRE) — Ghislain Houle, Executive Vice-President and Chief Financial Officer of CN (TSX: CNR) (NYSE: CNI), will address the 25th Annual CIBC Eastern Institutional Investor Conference on September 24, 2026, at 8:00 a.m. Eastern Time (ET).

CN will provide a live webcast via the Investors section of its website at www.cn.ca/investors. A replay of the webcast will be available following the event.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts:

Media Investment Community
Ashley Michnowski Jamie Lockwood
Senior Manager Vice-President
Media Relations Investor Relations & Special Projects
(438) 596-4329 (514) 399-0052
media@cn.ca investor.relations@cn.ca

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.